Addition Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2021

Developing of RNA-based genetic medicines using a non-viral insertion platform for chronic and rare diseases

Valuation $100–500M

Headcount <100

Total funding $100–500M

Unlock exact values

Company overview

Addition Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2021
Headquarters: South San Francisco, United States
Employees: 65
Open positions: 4
Dealroom signal: 83.3

Website ↗LinkedIn ↗

sub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorGenetics and genomicssectorChronic DiseasesectorGene TherapysectorSpinoutsectorGenome EngineeringsectorBiotech and PharmasectorRare DiseasessectorWoman FoundersectorDT and LSsectorscience-based

Valuation & funding

Addition Therapeutics funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Dec 2025	$100M	$400M	SR One · Osage University Partners · Abingworth · Bill & Melinda Gates Foundation	↗
SUPPORT PROGRAMOther financing	Jul 2021	$0	—	Bakar Bio Labs	↗
SPINOUTOther financing	Jun 2021	$0	—	University of California, Berkeley	—

Showing 3 recorded eventsUnlock the complete deal history →

Growth signals

Addition Therapeutics website traffic

Latest recorded traffic for Addition Therapeutics is 2.1K monthly website visits, down 44.7% over the last three months. Addition Therapeutics's team grew 1.6% over the past year.

Latest monthly visits2.1K 3-month web change-44.7% 1-year team growth+1.6%

Monthly website visits24 observations · Aug 2024–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Hiring

Open positions at Addition Therapeutics

Current openings linked to this company in Dealroom.

8 distinct openings shownExplore hiring signals →

Comparisons

Addition Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MTMuna TherapeuticsDiscovering and developing transformative therapeutics for neurodegenerative diseases	Copenhagen, Denmark	Operational	59	$79M	$292M
CTCyllene TherapeuticsNon-replicating HSV-1 gene therapy for neurological diseases.	Paris, France	Operational
OBOctarine BioHarnessing the powers of synthetic biology to develop rare and superior cannabinoids and psychedelic derivatives	Copenhagen, Denmark	Operational
BIBioSkrybBioSkryb is a developer of genomic amplification technologies that deliver unprecedented coverage for various gene sequencing applications	Durham, United States	Operational
ABArthex BiotechFocused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs	Paterna, Spain	Operational
OGOryzon GenomicsDevelops diagnostic and therapeutic tools	Cornellà de Llobregat, Spain	Operational
HGHeart GeneticsGenetics and Biotechnology	Cantanhede, Portugal	Operational
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Addition Therapeutics's talent

Book a demo to see the people

Team profiled 6 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Addition Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Series A 6 investors entered at this stage

SR One

Osage University Partners

Abingworth

Bill & Melinda Gates Foundation

Pivotal Life Sciences

BEVC

Other known 2 additional known investors

Bakar Bio Labs

University of California, Berkeley

Global footprint

Where Addition Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States98.2%

🇬🇧 United Kingdom1.8%

2 countries shown

In the news

Latest news about Addition Therapeutics

Recent press, funding announcements, and product moves mentioning Addition Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Addition Therapeutics

An AI-synthesized read of the highest-engagement posts about Addition Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Addition Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.